InspireMD, Inc. announced on December 9, 2024, that the first patient has been enrolled in its CGUARDIANS II clinical trial. This pivotal study is evaluating the CGuard Prime Carotid Stent System for use in Transcarotid Artery Revascularization (TCAR) procedures.
The enrollment was conducted by Dr. Patrick Muck at Good Samaritan Hospital in Cincinnati, Ohio, who also serves as a co-lead investigator for the study. This milestone is critical as InspireMD aims to address the expanding TCAR market, which accounts for approximately 30,000 procedures annually in the U.S.
The CGUARDIANS II study is a prospective, multi-center, single-arm trial designed to enroll a minimum of 50 evaluable patients. Its objective is to assess the acute device and technical success of CGuard Prime when used with an FDA-cleared TCAR neuro-protection system in high-risk patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.